Compound dossier · evidence, sources, and live market
Tesamorelin
Growth-hormone secretagogue Strong evidence 3 cited studies 84 live vendors
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), a 44-amino-acid peptide modified for greater stability against enzymatic degradation, and is classified as a growth-hormone secretagogue. In laboratory and preclinical contexts it is studied for its interaction with GHRH receptors and downstream signaling of the somatotropic axis. This index tracks research-use-only (RUO) vendor pricing for Tesamorelin to help researchers compare cost across suppliers.
Evidence brief
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue studied in multiple randomized controlled trials and pooled in a meta-analysis, almost entirely in people with HIV-associated abdominal fat accumulation.
first-party prices captured 37m ago
Compare by exact vialThe small sealed glass container a compound ships in. size: 5mg (24 vendors)10mg (76 vendors)20mg (14 vendors)
FDA-approved (Egrifta) for HIV-associated lipodystrophy only. The EU application was withdrawn in 2012; not approved in the EU or UK.Research use only — not medical advice.
These figures are what pepmg still publishes about price: the floor, the middle, the spread and how many sources we track, computed from listings we captured first-party and refreshed on the same schedule as always. We no longer publish the individual listings or the sellers behind them.
Computed from 117 in-stock listings across 84 sources we captured first-party, with bulk vials, blends and statistical outliers excluded so the figures compare like with like. The spread is the highest tracked price divided by the lowest — how much the same milligram varies depending on where you look. The chart is the daily minimum; days we did not capture are left out rather than filled in.
- What the research says about tesamorelin Strong evidence
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue studied in multiple randomized controlled trials and pooled in a meta-analysis, almost entirely in people with HIV-associated abdominal fat accumulation.
Read the full review →
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy PubMed ↗
Tesamorelin (Egrifta™) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far,…
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors PubMed ↗
Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV…
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD PubMed ↗
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
▸ Why compare $/mg for Tesamorelin?
Per-mg prices for Tesamorelin vary because vendors differ in synthesis scale, purity grade, lyophilization and fill quantity per vial, and how they amortize third-party testing across a batch. Comparing normalized $/mg across suppliers lets a researcher gauge whether a listing reflects genuine value or simply a smaller vial size or thinner documentation.
▸ Reading the COA
For Tesamorelin, confirm identity by mass spectrometry against the expected monoisotopic/average mass of the modified 44-residue GHRH sequence, and check that reported HPLC purity meets or exceeds a stated threshold (commonly 98%+ for research peptides). Because it is a long-chain peptide, watch for truncated or deletion sequences and residual synthesis byproducts (TFA counter-ion, acetate) noted on the COA; a lot-specific COA tied to the vial's batch number, not a generic template, is the meaningful signal for verifying the material.
▸ FAQ
▸ Same cluster
| CJC-1295 | $2.84/mg | vs Tesamorelin → |
| Ipamorelin | $2.60/mg | vs Tesamorelin → |
| NAD+ | $0.05/mg | vs Tesamorelin → |
| Sermorelin | $3.60/mg | vs Tesamorelin → |
| MOTS-c | $1.40/mg | vs Tesamorelin → |
| Epithalon | $1.10/mg | vs Tesamorelin → |
| SS-31 | $1.42/mg | vs Tesamorelin → |
| Humanin | $8.90/mg | vs Tesamorelin → |
| FOXO4-DRI | $6.26/mg | vs Tesamorelin → |
| GHRP-2 | $2.13/mg | vs Tesamorelin → |
| GHRP-6 | $2.10/mg | vs Tesamorelin → |
| Hexarelin | $4.90/mg | vs Tesamorelin → |
| MK-677 | $2.68/mg | vs Tesamorelin → |
| MK-777 | $3.45/mg | vs Tesamorelin → |